Due to their cardiovascular benefits, SGLT2 inhibitors are now recommended in the guidelines of key international diabetes associations (including the ADA and EASD) as second-line therapy for patients with T2DM who have established atherosclerotic CVD or high risk for cardiovascular events. This evidence concerns the gene SLC5A2 and diabetes mellitus.